Abstract 14P
Background
Host tumor microenvironment (TME) assessment is considered to play an important role in the prognostic and therapeutic predictions of breast cancer treatment. No consensus has been reached regarding evaluation methods despite reports of the utilization of tumor-infiltrating lymphocytes (TILs) for tumor immune microenvironment (TIME) monitoring. While the International Working Group recommends a tumor stromal evaluation, the timing of TIME assessment has not yet been established. Here, we focused on the assessment time and verified clinical predictions of neoadjuvant chemotherapy (NAC) effects using TILs.
Methods
Two hundred thirty-nine patients were treated with neoadjuvant chemotherapy (NAC). During the period from diagnostic needle biopsy to NAC initiation for breast cancer, the optimal evaluation timing was examined using a receiver operating characteristic (ROC) curve analysis.
Results
The prognostic analysis revealed that both disease-free survival (DFS) and overall survival (OS) were significantly prolonged in the short-term group (118 patients) relative to the long-term group (121 patients) (p = 0.020, p = 0.010, log-rank). A significant correlation between TILs and pathological complete response (pCR) was only observed in the short-term group (p = 0.033). Prognostic analysis revealed that in the short-term group, the high TIL group had a significantly better survival prognosis relative to the low TIL group (DFS: p = 0.001, OS: p = 0.021, log-rank). TILs were also found to be a significant factor affecting DFS in the univariate analysis (p = 0.004, hazard ratio = 0.115), as well as an independent factor affecting the DFS in a multivariate analysis (p = 0.008, hazard ratio = 0.130).
Conclusions
The timing of TIL assessment during NAC for breast cancer may be more sensitive index in the short term (≤35 days).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract
97P - The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer
Presenter: Jong Hoon Lee
Session: Poster display session
Resources:
Abstract